Bellerophon Therapeutics (NASDAQ:BLPH) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPHGet Rating) in a report issued on Wednesday. The firm set a “sell” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Price Performance

Shares of NASDAQ:BLPH opened at $1.45 on Wednesday. Bellerophon Therapeutics has a 1 year low of $0.67 and a 1 year high of $4.49. The business has a 50 day simple moving average of $1.27 and a two-hundred day simple moving average of $1.61. The firm has a market capitalization of $13.84 million, a PE ratio of -0.74 and a beta of -0.12.

Bellerophon Therapeutics (NASDAQ:BLPHGet Rating) last announced its quarterly earnings results on Monday, August 15th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.17. Equities research analysts expect that Bellerophon Therapeutics will post -2.31 EPS for the current fiscal year.

Institutional Trading of Bellerophon Therapeutics

An institutional investor recently bought a new position in Bellerophon Therapeutics stock. Sepio Capital LP purchased a new stake in Bellerophon Therapeutics, Inc. (NASDAQ:BLPHGet Rating) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 23,800 shares of the biotechnology company’s stock, valued at approximately $29,000. Sepio Capital LP owned 0.25% of Bellerophon Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 12.93% of the stock is currently owned by institutional investors and hedge funds.

Bellerophon Therapeutics Company Profile

(Get Rating)

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.

Recommended Stories

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.